Cell line · CVCL_8607
Papers41
1 to 20 of 41
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Combination of Three Herbal Components (ISL, Que, Meth) Suppresses Uveal Melanoma Growth via Gαq/MEK/YAP Axis Modulation and Apoptosis. | Biomedicines | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Preclinical response of uveal melanomas to the velcrin compound, BAY 2666605. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| GDF15 Reprograms the Microenvironment to Drive Liver Metastasis of Uveal Melanoma. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Network-based analysis reveals potential microRNA regulation of oncogenic pathways in SOX10-depleted uveal melanoma. | Cell Mol Life Sci | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A CRISPR-Cas13d cancer therapeutic enables selective elimination of uveal melanoma. | Mol Ther Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| UC2288 decreases the viability and metastatic activity of human Uveal melanoma cells via activating the AMPK/eIF2/ATF4 ER stress axis. | Eur J Pharmacol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Nutrient Availability Dictates Cancer Metabolism-Based Therapeutic Responses to Nononcology Drugs. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| The Discovery of α-Adrenoceptor Antagonists as a Potential New Treatment Option for Uveal Melanoma. | Biomolecules | 2025 | Its Methods give the RRID and name the line | PubMed | |
| CRISPR-Cas13d-Mediated Targeting of a Context-Specific Essential Gene Enables Selective Elimination of Uveal Melanoma. | bioRxiv | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Allele-specific depletion of GNAQ Q209L via siRNA or an rAAV2-shRNA vector induces selective toxicity in GNAQ Q209L uveal melanoma cells. | Mol Ther Oncol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| The LINC01315-encoded small protein YAPer-ORF competes with PRP4k to hijack YAP signaling to aberrantly promote cell growth. | Cell Death Differ | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Noninvasive Multicancer Detection Using DNA Hypomethylation of LINE-1 Retrotransposons. | Clin Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Imipridones inhibit tumor growth and improve survival in an orthotopic liver metastasis mouse model of human uveal melanoma. | Br J Cancer | 2024 | Its Methods give the RRID and name the line | PubMed | |
| The Chick Chorioallantoic Membrane as a Xenograft Model for the Quantitative Analysis of Uveal Melanoma Metastasis in Multiple Organs. | Cells | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Protein and mRNA Expression in Uveal Melanoma Cell Lines Are Related to GNA and BAP1 Mutation Status. | Invest Ophthalmol Vis Sci | 2024 | Cellosaurus cites it | PubMed | |
| Systems modeling of oncogenic G-protein and GPCR signaling reveals unexpected differences in downstream pathway activation. | NPJ Syst Biol Appl | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Uveal melanoma cell lines Mel270 and 92.1 exhibit a mesenchymal phenotype and sensitivity to the cytostatic effects of transforming growth factor beta in vitro. | Mol Vis | 2024 | Cellosaurus cites it | PubMed | |
| INPP5A phosphatase is a synthetic lethal target in GNAQ and GNA11-mutant melanomas. | Nat Cancer | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Cancer lineage-specific regulation of YAP responsive elements revealed through large-scale functional epigenomic screens. | Nat Commun | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Genetic screens reveal new targetable vulnerabilities in BAP1-deficient mesothelioma. | Cell Rep Med | 2023 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_8607/papers